Investor Database — 54,000+ VC, PE & angel contacts, the full list for $19.Get the list

iXLife Capital

Venture Capital Île-De-France, France ·Founded 2010

Overview

iXLife Capital is a French venture capital firm focused on investing in biotechnology companies that develop innovative therapies and devices for diseases such as cancer and neurological disorders. The firm identifies, evaluates, and supports biotech companies with creative approaches to medical advancements. The firm's investment strategy includes leading funding rounds and providing strategic support to portfolio companies. Notable investments include Quidditas Therapeutics, a Belgian biotech startup specializing in genome editing, and SeaBeLife, a French company developing treatments for dry age-related macular degeneration and severe acute hepatitis. iXLife Capital's team comprises professionals with extensive experience in the biotech sector, including Managing Partner Jean-Pierre Kinet, who has held positions at institutions like Harvard Medical School. The firm's approach emphasizes proactive investigation of promising market verticals within the healthcare and technology industries, aiming to partner with companies that have the potential to become leaders in their respective fields.

Investment Focus

Innovative biotech solutions
Experienced management teams
Potential for significant market impact

Portfolio Companies

ATANIS Biotech AGSeaBeLifeQuidditas Therapeutics

Reach iXLife Capital directly

Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.

Unlock full contacts →

Frequently asked questions about iXLife Capital

What sectors does iXLife Capital invest in?

iXLife Capital invests in Healthcare, Pharmaceuticals and Biotechnology, and is based in Île-De-France, France. iXLife Capital is listed as a venture capital in the ConnectSafely investor database.